logo-loader

Hemispherx Biopharma advances expanded access program for its therapy Ampligen

Published: 13:21 04 Jan 2019 EST

Hemispherx BioPharma Inc (NYSEAmerican:HEB) CEO Tom Equels tells Proactive Investors the Florida-based immunopharma company has shipped more than 300 recently manufactured vials of Ampligen to the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) clinical site at Incline Village, Nevada.

Equels says the vials will be used in the Expanded Access Program, authorized by the FDA to treat ME/CFS patients in an effort to expand compassionate care treatment to treat the disease where there is no commercially approved therapy.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

3 hours, 42 minutes ago